Research programme: skin disorders therapy - Bausch Health Companies
Latest Information Update: 19 Jul 2018
At a glance
- Originator Medicis Pharmaceutical Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 23 Mar 2009 Preclinical development appears to be ongoing in the US